Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. PDL BioPharma's Average Total Inventories for the quarter that ended in Jun. 2020 was $11.59 Mil. PDL BioPharma's Revenue for the
three
months ended in Jun. 2020 was $5.21 Mil.
PDL BioPharma's Inventory-to-Revenue for the quarter that ended in Jun. 2020 was 2.22.
PDL BioPharma's Inventory-to-Revenue for the quarter that ended in Jun. 2020
declined
from Mar. 2020 (4.20) to Mar. 2020 (2.22)
A decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
PDL BioPharma's Days Inventory for the
three
months ended in Jun. 2020 was 400.67.
Inventory Turnover measures how fast the company turns over its inventory within a year.
PDL BioPharma's Inventory Turnover for the quarter that ended in Jun. 2020 was 0.23.
PDL BioPharma Inventory-to-Revenue Historical Data
The historical data trend for PDL BioPharma's Inventory-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of PDL BioPharma's Inventory-to-Revenue
For the Biotechnology subindustry, PDL BioPharma's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PDL BioPharma's Inventory-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PDL BioPharma's Inventory-to-Revenue distribution charts can be found below:
* The bar in red indicates where PDL BioPharma's Inventory-to-Revenue falls into.
PDL BioPharma Inventory-to-Revenue Calculation
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
PDL BioPharma's Inventory-to-Revenue for the fiscal year that ended in Dec. 2019 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.
Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.
More Related Terms:
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
PDL BioPharma's Days Inventory for the
three
months ended in Jun. 2020 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PDL BioPharma Inventory-to-Revenue Related Terms
Thank you for viewing the detailed overview of PDL BioPharma's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
PDL BioPharma (PDL BioPharma) Business Description
PDL BioPharma Inc acquires and manages a portfolio of companies, products, royalty agreements and debt facilities in the biotech, pharmaceutical and medical device industries. The operating segments of the company are Medical Devices, Strategic Positions, Pharmaceutical and Income Generating Assets, of which key revenue is derived from the Pharmaceutical segment. The Pharmaceutical segment consists of revenue derived from branded prescription medicine products sold under the name Tekturna and Tekturna HCT in the U.S, and Rasilez and Rasilez HCT in the rest of the world (collectively, the Noden Products). Geographically, the company operates in Europe, North America, Asia and Other countries, of which prime revenue is generated from Asia and North America.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PDLI has been successfully added to your 